[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 27 of about 27
1. Maruya S, Shirasaki T, Nagaki T, Kakehata S, Kurotaki H, Mizukami H, Shinkawa H: Differential expression of topoisomerase IIalpha protein in salivary gland carcinomas: histogenetic and prognostic implications. BMC Cancer; 2009;9:72
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of topoisomerase IIalpha protein in salivary gland carcinomas: histogenetic and prognostic implications.
  • BACKGROUND: Salivary gland carcinomas are relatively uncommon heterogeneous malignancies characterized by locoregional invasion and distant metastasis.
  • Topoisomerase IIalpha (topoIIalpha), located at chromosome 17q21-22, is considered a major mediator of cell proliferation and DNA replication.
  • The purpose of this study was to evaluate the expression of topoIIalpha in various types of salivary gland tumors and its biological significance.
  • METHODS: The protein expression of topoIIalpha was evaluated immunohistochemically in formalin-fixed, paraffin-embedded tissue from 54 salivary gland carcinomas and 20 benign tumors (10 pleomorphic adenomas and 10 Warthin's tumors).
  • The primary salivary gland carcinoma specimens consisted of 17 adenoid cystic carcinomas, 7 adenocarcinomas not otherwise specified, 7 mucoepidermoid carcinomas, 6 salivary duct carcinomas, 3 acinic cell carcinomas, 3 carcinomas ex pleomorphic adenomas, 3 epithelial-myoepithelial carcinomas, 2 carcinosarcomas, 2 lymphoepithelial carcinomas, 2 myoepithelial carcinomas, 1 oncocytic carcinoma, and 1 squamous cell carcinoma.
  • RESULTS: Of the 54 primary salivary gland carcinomas, 38 (70%) showed positive expression (> or = 10%) of topoIIalpha protein, and 16 carcinomas (30%) and all benign tumors were negative (p < 0.001).
  • Expression of topoIIalpha was more frequently observed in salivary duct carcinoma, carcinoma ex pleomorphic adenoma, adenocarcinoma, and adenoid cystic carcinoma, solid type, and it was associated with advanced stage and shortened survival.
  • Furthermore, it may provide useful prognostic information and suggests the potential efficacy of topoIIalpha-targeting therapy in patients with salivary gland carcinoma.
  • [MeSH-major] Antigens, Neoplasm / biosynthesis. DNA Topoisomerases, Type II / biosynthesis. DNA-Binding Proteins / biosynthesis. Salivary Gland Neoplasms / enzymology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Head Neck. 2000 Aug;22(5):489-97 [10897109.001]
  • [Cites] Head Neck. 2008 May;30(5):680-3 [17972317.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):1061-7 [11948114.001]
  • [Cites] Clin Cancer Res. 2002 May;8(5):1107-16 [12006526.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Jun;3(6):430-40 [12042765.001]
  • [Cites] Lancet Oncol. 2002 Apr;3(4):235-43 [12067686.001]
  • [Cites] ORL J Otorhinolaryngol Relat Spec. 2003 Jan-Feb;65(1):26-32 [12624503.001]
  • [Cites] Am J Clin Pathol. 2003 May;119(5):715-22 [12760291.001]
  • [Cites] Clin Cancer Res. 2003 Oct 15;9(13):4682-8 [14581337.001]
  • [Cites] Int J Oncol. 2004 Jan;24(1):201-9 [14654958.001]
  • [Cites] Anticancer Res. 2003 Sep-Oct;23(5A):3965-70 [14666704.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):944-6 [14871971.001]
  • [Cites] J Otolaryngol. 2003 Oct;32(5):328-31 [14974865.001]
  • [Cites] Mod Pathol. 2004 Jun;17(6):637-45 [15044918.001]
  • [Cites] Arch Otolaryngol. 1984 Mar;110(3):172-6 [6322732.001]
  • [Cites] Cancer. 1984 Sep 15;54(6):1062-9 [6088017.001]
  • [Cites] Oncology (Williston Park). 1998 May;12(5):671-80; discussion 683 [9597678.001]
  • [Cites] Pathol Res Pract. 2005;200(11-12):791-9 [15792122.001]
  • [Cites] Breast Cancer Res. 2005;7(3):R374-84 [15987433.001]
  • [Cites] J Clin Oncol. 2006 Jun 10;24(17):2673-8 [16763282.001]
  • [Cites] Cancer Treat Rev. 2007 Feb;33(1):64-77 [17113234.001]
  • [Cites] Oral Oncol. 2007 Sep;43(8):735-41 [17113340.001]
  • [Cites] Head Neck. 2007 Nov;29(11):1002-9 [17427971.001]
  • [Cites] Hum Pathol. 2001 Jun;32(6):596-604 [11431714.001]
  • (PMID = 19250538.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / DNA-Binding Proteins; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  • [Other-IDs] NLM/ PMC2654461
  •  go-up   go-down


2. Darling MR, Tsai S, Jackson-Boeters L, Daley TD, Diamandis EP: Human kallikrein 8 expression in salivary gland tumors. Head Neck Pathol; 2008 Sep;2(3):169-74
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human kallikrein 8 expression in salivary gland tumors.
  • The human kallikrein 8 protein (KLK8) is expressed in many normal tissues including esophagus, skin, testis, tonsil, kidney, breast, and salivary gland, and is found in biological fluids including breast milk, amniotic fluid, seminal fluid and serum.
  • The aim of this study was to determine whether KLK8 is expressed in salivary gland tissues and salivary gland tumors (both benign and malignant), in order to compare normal with tumor tissues.
  • Pleomorphic adenomas, adenoid cystic carcinomas, polymorphous low grade adenocarcinomas, acinic cell carcinomas, mucoepidermoid carcinomas, and adenocarcinomas NOS of both minor and major salivary glands were examined.
  • The results of this study indicate that most salivary gland tumors show high levels of expression of KLK8.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma, Pleomorphic / metabolism. Kallikreins / metabolism. Salivary Gland Neoplasms / metabolism. Salivary Glands, Minor / metabolism

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Histochem Cytochem. 2006 Mar;54(3):337-42 [16286664.001]
  • [Cites] Br J Cancer. 2004 Jan 12;90(1):167-72 [14710225.001]
  • [Cites] Oncol Rep. 2004 Jun;11(6):1153-9 [15138549.001]
  • [Cites] Mol Cancer Res. 2004 May;2(5):257-80 [15192120.001]
  • [Cites] J Natl Cancer Inst. 1993 Feb 3;85(3):200-6 [8423624.001]
  • [Cites] Gene. 1998 Jun 15;213(1-2):9-16 [9714609.001]
  • [Cites] Int J Cancer. 1998 Oct 23;79(5):502-8 [9761120.001]
  • [Cites] Clin Chem. 1999 Jun;45(6 Pt 1):790-9 [10351987.001]
  • [Cites] Nat Rev Cancer. 2004 Nov;4(11):876-90 [15516960.001]
  • [Cites] Cancer Lett. 2005 Jun 16;224(1):1-22 [15911097.001]
  • [Cites] FEBS Lett. 2005 Dec 19;579(30):6879-84 [16337200.001]
  • [Cites] Clin Cancer Res. 2006 Mar 1;12(5):1487-93 [16533772.001]
  • [Cites] Biol Chem. 2006 Jun;387(6):643-52 [16800725.001]
  • [Cites] Biol Chem. 2006 Jun;387(6):653-63 [16800726.001]
  • [Cites] Biol Chem. 2006 Jun;387(6):723-31 [16800733.001]
  • [Cites] Int J Biol Markers. 2006 Apr-Jun;21(2):106-10 [16847813.001]
  • [Cites] Tumour Biol. 2006;27(5):274-82 [16888409.001]
  • [Cites] Cancer Res. 2006 Dec 15;66(24):11763-70 [17178872.001]
  • [Cites] Int J Biol Markers. 2006 Oct-Dec;21(4):201-5 [17177156.001]
  • [Cites] Clin Chim Acta. 2007 May;381(1):78-84 [17382920.001]
  • [Cites] J Biol Chem. 2007 Nov 2;282(44):31852-64 [17823117.001]
  • [Cites] Biochim Biophys Acta. 2007 Sep;1776(1):22-31 [17629406.001]
  • [Cites] Breast Cancer Res Treat. 2007 Mar;102(1):7-18 [16897430.001]
  • [Cites] Trends Endocrinol Metab. 2000 Mar;11(2):54-60 [10675891.001]
  • [Cites] Endocr Rev. 2001 Apr;22(2):184-204 [11294823.001]
  • [Cites] Clin Cancer Res. 2001 Apr;7(4):806-11 [11309326.001]
  • [Cites] Expert Rev Mol Diagn. 2001 Jul;1(2):182-90 [11901813.001]
  • [Cites] Clin Chem. 2002 Aug;48(8):1198-205 [12142373.001]
  • [Cites] Biol Chem. 2002 Jul-Aug;383(7-8):1045-57 [12437087.001]
  • [Cites] Clin Chem. 2003 Jan;49(1):87-96 [12507964.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2223-7 [12727843.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):2771-4 [12782581.001]
  • [Cites] Am J Obstet Gynecol. 2004 Jan;190(1):60-6 [14749636.001]
  • (PMID = 20614312.001).
  • [ISSN] 1936-0568
  • [Journal-full-title] Head and neck pathology
  • [ISO-abbreviation] Head Neck Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.21.- / KLK8 protein, human; EC 3.4.21.- / Kallikreins
  • [Other-IDs] NLM/ PMC2807567
  • [Keywords] NOTNLM ; Human kallikrein 8 / Immunohistochemistry / Kallikreins / Prognostic markers / Salivary gland tumors
  •  go-up   go-down


3. Arathi N, Bage AM: Polymorphous low-grade adenocarcinoma of parotid gland: a rare occurrence. Indian J Pathol Microbiol; 2009 Jan-Mar;52(1):103-5
Genetic Alliance. consumer health - Polymorphous low-grade adenocarcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphous low-grade adenocarcinoma of parotid gland: a rare occurrence.
  • Polymorphous low-grade adenocarcinoma (PLGA) is a rare salivary gland malignant tumor of low aggressiveness, commonly occurring in minor salivary glands.
  • Its occurrence in major salivary gland has been documented albeit rarely.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Parotid Gland / pathology. Parotid Neoplasms / diagnosis. Parotid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Indian J Pathol Microbiol. 2010 Jan-Mar;53(1):166-7 [20090256.001]
  • (PMID = 19136798.001).
  • [ISSN] 0974-5130
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


Advertisement
4. Curran AE, Allen CM, Beck FM, Damm DD, Murrah VA: Distinctive pattern of glial fibrillary acidic protein immunoreactivity useful in distinguishing fragmented pleomorphic adenoma, canalicular adenoma and polymorphous low grade adenocarcinoma of minor salivary glands. Head Neck Pathol; 2007 Sep;1(1):27-32
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinctive pattern of glial fibrillary acidic protein immunoreactivity useful in distinguishing fragmented pleomorphic adenoma, canalicular adenoma and polymorphous low grade adenocarcinoma of minor salivary glands.
  • OBJECTIVES: Immunohistochemistry (IHC) can be helpful in the diagnosis of minor salivary gland neoplasms including those that have been incisionally biopsied or fragmented during surgery that do not contain key diagnostic features on hematoxylin and eosin sections.
  • IHC has been used as an adjunct to distinguish among many salivary gland neoplasms using both qualitative and quantitative methods.
  • The objective of this study was to determine whether a distinctive immunoreactivity staining pattern to GFAP can be consistently observed among three selected minor salivary gland neoplasms and thus serve as a diagnostic adjunctive procedure.
  • STUDY DESIGN: Glial fibrillary acidic protein (GFAP) reactivity was examined among 78 minor salivary gland neoplasms: 27 canalicular adenomas (CAA), 21 pleomorphic adenomas (PA) and 30 polymorphous low grade adenocarcinomas (PLGA).
  • Because each of these neoplasms requires a different treatment approach, this can be of major significance.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenoma, Pleomorphic / diagnosis. Glial Fibrillary Acidic Protein / metabolism. Salivary Gland Neoplasms / diagnosis. Salivary Glands, Minor / pathology

  • Genetic Alliance. consumer health - Polymorphous low-grade adenocarcinoma.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Pathol Lab Med. 2000 Mar;124(3):401-5 [10705394.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001 Feb;91(2):194-9 [11174597.001]
  • [Cites] Am J Clin Pathol. 1977 Mar;67(3):272-8 [842502.001]
  • [Cites] Am J Pathol. 1990 Nov;137(5):1143-55 [1700618.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1991;418(4):339-48 [1708927.001]
  • [Cites] J Laryngol Otol. 1991 Dec;105(12):1057-60 [1664847.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1997 Jun;83(6):691-5 [9195625.001]
  • [Cites] J Neurosurg. 1998 Dec;89(6):997-1006 [9833827.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1999 Mar;87(3):346-50 [10102598.001]
  • [Cites] Electrophoresis. 1999 Apr-May;20(4-5):1087-91 [10344289.001]
  • [Cites] Cancer. 1999 Jul 15;86(2):207-19 [10421256.001]
  • (PMID = 20614277.001).
  • [ISSN] 1936-0568
  • [Journal-full-title] Head and neck pathology
  • [ISO-abbreviation] Head Neck Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glial Fibrillary Acidic Protein
  • [Other-IDs] NLM/ PMC2807497
  • [Keywords] NOTNLM ; Canalicular adenoma / Glial fibrillary acidic protein / Immunohistochemistry / Pleomorphic adenoma / Polymorphous low-grade adenocarcinoma / Salivary gland neoplasms
  •  go-up   go-down


5. Tarakji B, Nassani MZ, Sloan P: Immunohistochemical expression of estrogens and progesterone receptors in carcinoma ex pleomorphic adenoma-undifferentiated and adenocarcinoma types. Med Oral Patol Oral Cir Bucal; 2010 May;15(3):e432-6
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical expression of estrogens and progesterone receptors in carcinoma ex pleomorphic adenoma-undifferentiated and adenocarcinoma types.
  • Cancer of the salivary gland is one of the common cancers in the head and the neck regions.
  • This type of cancer develops in the minor and the major salivary glands, and it sometimes metastasizes to other organs, particularly the lung.
  • Morphologic mimicry and similarity in the expression of steroid hormone receptors between salivary gland tumours and breast tumours are well-known phenomena and are occasionally debated in the field of surgical pathology.
  • Previous studies of the expression of estrogens and progesterone receptors in salivary gland tumours have reported conflicting results.
  • STUDY DESIGN: 27 cases of carcinoma arising in pleomorphic adenoma (undifferentiated and adenocarcinoma types) were examined.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma, Pleomorphic / metabolism. Neoplasms, Multiple Primary / metabolism. Receptors, Estrogen / biosynthesis. Receptors, Progesterone / biosynthesis. Salivary Gland Neoplasms / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20038908.001).
  • [ISSN] 1698-6946
  • [Journal-full-title] Medicina oral, patología oral y cirugía bucal
  • [ISO-abbreviation] Med Oral Patol Oral Cir Bucal
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  •  go-up   go-down


6. Pintor MF, Figueroa L, Martínez B: Polymorphous low grade adenocarcinoma: review and case report. Med Oral Patol Oral Cir Bucal; 2007 Dec;12(8):E549-51
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphous low grade adenocarcinoma: review and case report.
  • Polymorphous Low-Grade Adenocarcinoma is a rare, malignant salivary gland tumor, which is found almost exclusively in minor salivary glands.
  • It is rare in major salivary glands.
  • An incisional biopsy was carried out, and once the polymorphous low-grade adenocarcinoma diagnosis had been stated, the patient was sent to the Head and Neck Surgery Service of the Military Hospital, where the lesion was treated by wide surgical excision followed by radiation therapy.
  • [MeSH-major] Adenocarcinoma. Salivary Gland Neoplasms

  • Genetic Alliance. consumer health - Polymorphous low-grade adenocarcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18059236.001).
  • [ISSN] 1698-6946
  • [Journal-full-title] Medicina oral, patología oral y cirugía bucal
  • [ISO-abbreviation] Med Oral Patol Oral Cir Bucal
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 10
  •  go-up   go-down


7. Ruíz-Godoy L, Suárez L, Mosqueda A, Meneses A: Polymorphous low-grade adenocarcinoma of the parotid gland. Case report and review of the literature. Med Oral Patol Oral Cir Bucal; 2007 Jan;12(1):E30-3
Genetic Alliance. consumer health - Polymorphous low-grade adenocarcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphous low-grade adenocarcinoma of the parotid gland. Case report and review of the literature.
  • Polymorphous low-grade adenocarcinoma (PLGA) is difficult to diagnose both clinically and histologically due to its indolent presentation, and because of its morphological diversity that includes several microscopic patterns.
  • The aggressive biologic behavior seen in minor salivary glands as compared to major glands is apparently associated histologically to a predominance of the papillary pattern in the former.
  • Biologic behavior of PLGA in the major salivary glands is uncertain, as some cases have developed recurrences and metastases independently of the presence of a papillary pattern.
  • A case of PLGA originated de novo in parotid gland is presented a 60 year-old male, treatment was surgically excised through superficial parotidectomy and to postoperative radiotherapy (46 Gy).
  • [MeSH-major] Adenocarcinoma / pathology. Parotid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17195824.001).
  • [ISSN] 1698-6946
  • [Journal-full-title] Medicina oral, patología oral y cirugía bucal
  • [ISO-abbreviation] Med Oral Patol Oral Cir Bucal
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 18
  •  go-up   go-down


8. Tanvetyanon T, Qin D, Padhya T, McCaffrey J, Zhu W, Boulware D, DeConti R, Trotti A: Outcomes of postoperative concurrent chemoradiotherapy for locally advanced major salivary gland carcinoma. Arch Otolaryngol Head Neck Surg; 2009 Jul;135(7):687-92
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of postoperative concurrent chemoradiotherapy for locally advanced major salivary gland carcinoma.
  • OBJECTIVE: To investigate the potential value of postoperative concurrent chemoradiation among patients with high-risk salivary gland carcinomas.
  • PATIENTS: A total of 24 patients, 12 with major salivary gland carcinoma who were treated with postoperative concurrent chemoradiotherapy from 1998 to 2007 (chemoradiation group), and a control group of 12 patients treated with postoperative radiation alone.
  • CONCLUSIONS: Locally advanced or high-grade salivary gland carcinomas follow an aggressive clinical course.
  • [MeSH-major] Adenocarcinoma / surgery. Salivary Gland Neoplasms / mortality. Salivary Gland Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19620591.001).
  • [ISSN] 1538-361X
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Darling MR, Jackson-Boeters L, Daley TD, Diamandis EP: Human kallikrein 13 expression in salivary gland tumors. Int J Biol Markers; 2006 Apr-Jun;21(2):106-10
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human kallikrein 13 expression in salivary gland tumors.
  • Petraki et al have previously described presence of hK13 in salivary gland tissue, localized to duct epithelia and some acinar cells.
  • The aim of this study was to determine whether hK13 is expressed in salivary gland tissues and salivary gland tumors (both benign and malignant), in order to compare normal with tumor tissues.
  • Pleomorphic adenomas (PA), adenoid cystic carcinomas (ACC), polymorphous low grade adenocarcinomas (PLGA), acinic cell carcinomas (ACI), mucoepidermoid carcinomas (MEC) and adenocarcinomas not otherwise specified (ANOS) of both minor and major salivary glands were examined.
  • The results of this study indicate that most salivary gland tumors show high levels of expression of hK13.
  • Overall, staining in PA was significantly less than that seen in normal salivary gland tissue.
  • PLGA, ACC and ANOS each stained significantly more than normal salivary gland tissue while MEC and ACI did not.
  • In conclusion, we demonstrate the high expression of hK13 in several common salivary gland tumors.
  • [MeSH-major] Biomarkers, Tumor. Carcinoma, Adenoid Cystic / metabolism. Gene Expression Regulation, Neoplastic. Kallikreins / biosynthesis. Mouth Mucosa / metabolism. Salivary Gland Neoplasms / genetics
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenoma, Pleomorphic / metabolism. Carcinoma, Mucoepidermoid / metabolism. Humans. Immunohistochemistry. Prognosis. Salivary Glands / metabolism

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16847813.001).
  • [ISSN] 0393-6155
  • [Journal-full-title] The International journal of biological markers
  • [ISO-abbreviation] Int. J. Biol. Markers
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.21.- / KLK13 protein, human; EC 3.4.21.- / Kallikreins
  •  go-up   go-down


10. Kupferman ME, de la Garza GO, Santillan AA, Williams MD, Varghese BT, Huh W, Roberts D, Weber RS: Outcomes of pediatric patients with malignancies of the major salivary glands. Ann Surg Oncol; 2010 Dec;17(12):3301-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of pediatric patients with malignancies of the major salivary glands.
  • BACKGROUND: To report the outcomes and early to long term treatment complications among pediatric patients with major salivary gland malignancies treated at a single institution.
  • Patients less than 19 years of age with a diagnosis of a major salivary gland malignancy were identified at the M. D.
  • The majority of tumors arose in the parotid gland (83%), and the most common pathology was mucoepidermoid carcinoma (46%).
  • CONCLUSIONS: Survival of pediatric patients with major salivary gland carcinomas is favorable.
  • [MeSH-major] Adenocarcinoma / therapy. Carcinoma, Adenoid Cystic / therapy. Carcinoma, Mucoepidermoid / therapy. Carcinoma, Squamous Cell / therapy. Salivary Gland Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20585877.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Stodulski D, Rzepko R, Kowalska B, Stankiewicz C: [Carcinoma ex pleomorphic adenoma of major salivary glands--a clinicopathologic review]. Otolaryngol Pol; 2007;61(5):687-93
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Carcinoma ex pleomorphic adenoma of major salivary glands--a clinicopathologic review].
  • BACKGROUND: Pleomorphic adenoma (PA) is the most common neoplasm of the major salivary glands.
  • In 15 cases, tumor was localized in the parotid and in 4 in the submandibular gland.
  • The most common malignant component in CXPA was adenocarcinoma (9 cases) and undifferentiated carcinoma (6 cases).
  • The best method of prevention and treatment of CXPA is early and radical removal of all major salivary glands tumors.
  • [MeSH-major] Adenoma, Pleomorphic / pathology. Carcinoma / pathology. Neoplasms, Multiple Primary / pathology. Salivary Gland Neoplasms / pathology. Salivary Glands / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18552001.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


12. Akrish S, Peled M, Ben-Izhak O, Nagler RM: Malignant salivary gland tumors and cyclo-oxygenase-2: a histopathological and immunohistochemical analysis with implications on histogenesis. Oral Oncol; 2009 Dec;45(12):1044-50
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant salivary gland tumors and cyclo-oxygenase-2: a histopathological and immunohistochemical analysis with implications on histogenesis.
  • The classification system for malignant salivary gland tumors (MST) is largely dependent on its histogenesis.
  • Fifty six primary major and minor gland MST were stained with anti-cox-2 antibody and rated with a combined score that added a scale of intensity to the percentage of tumor cells that overexpressed the cox-2 protein.
  • Strong cox-2 overexpression was noted in all MST of proposed excretory duct origin: salivary duct carcinoma (100%), mucoepidermoid carcinoma (MEC) (92%), and adenocarcinoma nos (AdC nos) (83%).
  • Negative expression was noted in all tumors of proposed intercalated duct origin (adenoid cystic carcinoma, basal cell adenocarcinoma and acinic cell carcinoma) with the exception of one case of polymorphous low grade adenocarcinoma.
  • Strong cox-2 overexpression was noted in the epidermoid cells of MEC, abluminal duct cells surrounding the duct-like structures and ductal cells of AdC nos and salivary duct carcinoma.
  • [MeSH-major] Biomarkers, Tumor / analysis. Cyclooxygenase 2 / analysis. Salivary Gland Neoplasms / enzymology. Salivary Gland Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19729335.001).
  • [ISSN] 1879-0593
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


13. Aydin E, Turkoglu S, Ozen O, Akkuzu B: Mucinous cystadenocarcinoma of a minor salivary gland in the upper lip: case report. Auris Nasus Larynx; 2005 Sep;32(3):301-4
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous cystadenocarcinoma of a minor salivary gland in the upper lip: case report.
  • Mucinous cystadenocarcinoma of the salivary gland is a rare entity that has only recently been described.
  • Only a small proportion of salivary gland tumors are adenocarcinomas.
  • Most mucinous cystadenocarcinomas affect the major salivary glands, particularly the parotid.
  • These are low-grade malignancies, and most that occur in the minor salivary glands show very little aggressive behavior.
  • The differential diagnosis includes mucoepidermoid carcinoma, acinic cell carcinoma, salivary duct carcinoma, nasal adenocarcinoma, and metastatic carcinoma.
  • The pathological diagnosis was low-grade mucinous cystadenocarcinoma of a minor salivary gland.
  • [MeSH-major] Cystadenocarcinoma, Mucinous / diagnosis. Cystadenocarcinoma, Mucinous / pathology. Lip / surgery. Salivary Gland Neoplasms / diagnosis. Salivary Gland Neoplasms / pathology
  • [MeSH-minor] Aged, 80 and over. Follow-Up Studies. Humans. Male. Salivary Glands, Minor / pathology. Salivary Glands, Minor / surgery. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15923100.001).
  • [ISSN] 0385-8146
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


14. Vacchi-Suzzi M, Bocciolini C, Bertarelli C, Dall'Olio D: Ki-67 proliferation rate as a prognostic marker in major salivary gland carcinomas. Ann Otol Rhinol Laryngol; 2010 Oct;119(10):677-83

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ki-67 proliferation rate as a prognostic marker in major salivary gland carcinomas.
  • OBJECTIVES: The study was performed to evaluate the prognostic relevance of cell proliferation associated with Ki-67/ Mib-1 immunostaining in malignant tumors of the major salivary glands.
  • METHODS: Cell proliferation was evaluated by Mib-1 antibody against Ki-67 antigen in 41 patients with cancer of the parotid or submandibular glands, including 14 acinic cell carcinomas, 12 ductal carcinomas, 7 mucoepidermoid carcinomas, 5 carcinomas ex pleomorphic adenoma, 1 adenoid cystic carcinoma, 1 undifferentiated carcinoma, and 1 polymorphous low-grade adenocarcinoma.
  • CONCLUSIONS: To our knowledge, this is the first study to stratify different risk classes in early T1-T2 or N0 malignant tumors of the major salivary glands that identified aggressive lesions with elevated Ki-67 expression at an initial stage.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers / analysis. Carcinoma, Acinar Cell / mortality. Carcinoma, Adenoid Cystic / mortality. Carcinoma, Ductal / mortality. Carcinoma, Mucoepidermoid / mortality. Disease-Free Survival. Female. Humans. Immunohistochemistry. Male. Middle Aged. Parotid Neoplasms / mortality. Prognosis. Salivary Gland Neoplasms / mortality. Submandibular Gland Neoplasms / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21049853.001).
  • [ISSN] 0003-4894
  • [Journal-full-title] The Annals of otology, rhinology, and laryngology
  • [ISO-abbreviation] Ann. Otol. Rhinol. Laryngol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Ki-67 Antigen
  •  go-up   go-down


15. Chen AM, Granchi PJ, Garcia J, Bucci MK, Fu KK, Eisele DW: Local-regional recurrence after surgery without postoperative irradiation for carcinomas of the major salivary glands: implications for adjuvant therapy. Int J Radiat Oncol Biol Phys; 2007 Mar 15;67(4):982-7
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Local-regional recurrence after surgery without postoperative irradiation for carcinomas of the major salivary glands: implications for adjuvant therapy.
  • PURPOSE: To determine factors predictive of local-regional recurrence (LRR) after surgery alone for carcinomas of the major salivary glands in an attempt to evaluate the potential role of postoperative radiation therapy.
  • METHODS AND MATERIALS: Between 1960 and 2004, 207 patients with carcinomas of the major salivary glands were treated with definitive surgery without postoperative radiation therapy.
  • Histology was: 67 mucoepidermoid (32%), 50 adenoid cystic (24%), 34 acinic cell (16%), 23 malignant mixed (11%), 16 adenocarcinoma (8%), 6 oncocytic (3%), 6 myoepithelial (3%), and 5 other (2%).
  • CONCLUSION: Lymph node metastasis, high tumor grade, positive margins, and T3-4 stage predict for significant rates of LRR after surgery for carcinomas of the major salivary glands.
  • [MeSH-major] Carcinoma / secondary. Carcinoma / surgery. Neoplasm Recurrence, Local. Salivary Gland Neoplasms / pathology. Salivary Gland Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17241753.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Darling MR, Tsai S, Jackson-Boeters L, Daley TD, Diamandis EP: Human kallikrein 3 (prostate specific antigen) and human kallikrein 5 expression in salivary gland tumors. Int J Biol Markers; 2006 Oct-Dec;21(4):201-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human kallikrein 3 (prostate specific antigen) and human kallikrein 5 expression in salivary gland tumors.
  • The human kallikrein 5 protein (hK5) is expressed in many normal tissues, most notably in skin, breast, salivary gland and esophagus.
  • Human kallikrein 3 (hK3; prostate-specific antigen) is the most useful marker for adenocarcinoma of the prostate gland.
  • The aim of this study was to determine whether hK3 and hK5 are expressed in salivary gland tissues and salivary gland tumors (both benign and malignant), in order to compare normal with tumor tissues.
  • Pleomorphic adenomas, adenoid cystic carcinomas, polymorphous low-grade adenocarcinomas, acinic cell carcinomas, mucoepidermoid carcinomas and adenocarcinomas not otherwise specified of both minor and major salivary glands were examined.
  • The results of this study indicate that most salivary gland tumors do not show high levels of expression of hK5.
  • Staining was most prominent in keratinizing epithelia in pleomorphic adenomas. hK3 is not expressed in salivary gland tumors.
  • [MeSH-major] Biomarkers, Tumor / analysis. Kallikreins / analysis. Prostate-Specific Antigen / analysis. Salivary Gland Neoplasms / chemistry

  • MedlinePlus Health Information. consumer health - Prostate Cancer Screening.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17177156.001).
  • [ISSN] 0393-6155
  • [Journal-full-title] The International journal of biological markers
  • [ISO-abbreviation] Int. J. Biol. Markers
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.21.- / Kallikreins; EC 3.4.21.- / kallikrein 5, human; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


17. Suzuki H, Yamauchi G, Hashimoto K: Clear cell carcinoma of the mandibular gingiva 'minor salivary gland': a case report with immunohistochemical study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Mar;103(3):e36-40
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell carcinoma of the mandibular gingiva 'minor salivary gland': a case report with immunohistochemical study.
  • Clear cell carcinoma is a rare neoplasm that arises in salivary glands.
  • They are more frequent in the intraoral minor salivary glands than the major salivary glands.
  • This report examined the immunohistochemical characteristics of clear cell carcinoma, minor salivary gland, and reviewed the existing literature.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Gingival Neoplasms / pathology. Salivary Gland Neoplasms / pathology. Salivary Glands, Minor / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17321437.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 68238-35-7 / Keratins
  • [Number-of-references] 14
  •  go-up   go-down


18. Bandyopadhyay A, Das TK, Raha K, Hati GC, Mitra PK, Dasgupta A: A study of fine needle aspiration cytology of salivary gland lesions with histopathological corroboration. J Indian Med Assoc; 2005 Jun;103(6):312-4, 316
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A study of fine needle aspiration cytology of salivary gland lesions with histopathological corroboration.
  • The diagnostic utility of fine needle aspiration cytology as initial work up of salivary gland enlargement was assessed in one hundred and eighty-five salivary gland specimens over three years period and corroborated with histopathology, whenever feasible.
  • All smears were evaluated according to cell size, amount of cytoplasm, cytologic atypia and presence of lymphocytes. (a) Variable cytologic appearances of pleomorphic salivary adenoma were observed. (b) Cellular pleomorphic adenoma and adenoid cystic carcinoma showed basaloid cell features. (c) Tumours with intermediate size cells and bland cytology included low grade muco-epidermoid carcinoma and cystic lesions. (d) Warthin's tumour, oncocytoma, salivary duct carcinoma and high grade muco-epidermoid carcinoma revealed large cells and abundant cytoplasm with or without atypia.
  • A major diagnostic categories were inflammatory lesions (n = 7 5), cystic lesions (n = 9), benign tumours (n = 81), malignant neoplasms (n = 1 8) and normal acinar pattern (n = 2).
  • Malignant tumours included muco-epidermoid carcinoma (n = 5), adenoid cystic carcinoma (n = 3), acinic cell carcinoma (n = 2), adenocarcinoma (n= 2), squamous cell carcinoma (n = 1), undifferentiated carcinoma (n= 4) and malignant lymphoma (n = 1).
  • So it can be concluded that fine needle aspiration cytology can play important role in early diagnosis and subsequent therapeutic planning of salivary gland lesions.
  • [MeSH-major] Adenoma / pathology. Salivary Gland Neoplasms / pathology. Sialadenitis / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16225156.001).
  • [ISSN] 0019-5847
  • [Journal-full-title] Journal of the Indian Medical Association
  • [ISO-abbreviation] J Indian Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


19. Caloglu M, Yurut-Caloglu V, Altaner S, Huseyinova G, Unlu E, Karagol H, Uzal C: Oncocytic carcinoma of the parotid gland. Onkologie; 2006 Sep;29(8-9):388-90

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncocytic carcinoma of the parotid gland.
  • BACKGROUND: Oncocytic carcinoma is a rare tumor of major salivary glands.
  • CASE REPORT: A 58-year old man presented with a recurrent mass in the left parotid gland with a prior diagnosis of monomorphic adenoma in the same localization which had been treated by tumor excision in July 2002.
  • CONCLUSION: For an accurate approach in the management of patients, oncocytic adenocarcinoma should be considered in the differential diagnosis of lesions of the parotid gland, most of which are benign.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16974117.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


20. Chen AM, Garcia J, Lee NY, Bucci MK, Eisele DW: Patterns of nodal relapse after surgery and postoperative radiation therapy for carcinomas of the major and minor salivary glands: what is the role of elective neck irradiation? Int J Radiat Oncol Biol Phys; 2007 Mar 15;67(4):988-94
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of nodal relapse after surgery and postoperative radiation therapy for carcinomas of the major and minor salivary glands: what is the role of elective neck irradiation?
  • PURPOSE: To evaluate the incidence of nodal relapses from carcinomas of the salivary glands among patients with clinically negative necks in an attempt to determine the potential utility of elective neck irradiation (ENI).
  • METHODS AND MATERIALS: Between 1960 and 2004, 251 patients with clinically N0 carcinomas of the salivary glands were treated with surgery and postoperative radiation therapy.
  • Histology was: adenoid cystic (84 patients), mucoepidermoid (60 patients), adenocarcinoma (58 patients), acinic cell (21 patients), undifferentiated (11 patients), carcinoma ex pleomorphic adenoma (7 patients), squamous cell (7 patients), and salivary duct carcinoma (3 patients); 131 patients (52%) had ENI.
  • The highest crude rates of nodal relapse among those treated without ENI were found in patients with squamous cell carcinoma (67%), undifferentiated carcinoma (50%), adenocarcinoma (34%), and mucoepidermoid carcinoma (29%).
  • [MeSH-major] Carcinoma / secondary. Lymphatic Irradiation. Salivary Gland Neoplasms / pathology. Salivary Glands, Minor / pathology

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17234357.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Salem A, Phillips JS, Joseph JA, O'Donovan DG, Jani P: Basal cell adenocarcinoma of the ethmoid sinuses. J Laryngol Otol; 2007 Sep;121(9):889-91

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell adenocarcinoma of the ethmoid sinuses.
  • Basal cell adenocarcinoma is a rare and relatively recently characterised malignant salivary gland tumour.
  • It accounts for 5 per cent of parotid gland tumours and 1 per cent of salivary gland malignancies.
  • It is very rarely documented in anatomical sites other than the major salivary glands.
  • Basal cell adenocarcinoma has only been described once before in the ethmoid sinus.
  • We report a case of basal cell adenocarcinoma in the ethmoid sinus, extending into the right orbit and anterior cranial fossa.
  • [MeSH-major] Adenocarcinoma. Ethmoid Sinus. Paranasal Sinus Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17295935.001).
  • [ISSN] 1748-5460
  • [Journal-full-title] The Journal of laryngology and otology
  • [ISO-abbreviation] J Laryngol Otol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


22. Sun G, Yang X, Tang E, Wen J, Lu M, Hu Q: The treatment of sublingual gland tumours. Int J Oral Maxillofac Surg; 2010 Sep;39(9):863-8
MedlinePlus Health Information. consumer health - Salivary Gland Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The treatment of sublingual gland tumours.
  • This study assessed the clinical and histological features and therapeutic efficacy of 25 cases of sublingual gland tumours from 1998 to 2008.
  • 21 cases were malignant sublingual gland tumours (84%) and of these, 18 were adenoid cystic carcinoma (86%).
  • Adenoid cystic carcinoma was mainly of the histological type, and the other histological classifications included mucoepidermoid carcinoma, pleomorphic adenoma, myoepithelioma, oncocytoma and polymorphous low-grade adenocarcinoma.
  • Sublingual gland tumours are rare and most are malignant.
  • For malignant sublingual gland tumours, early diagnosis and aggressive surgical treatment, especially for tumours with nerve involvement, is the key to improving prognosis.
  • Free radial forearm flap or pectoralis major myocutaneous flap are appropriate methods for mouth floor reconstruction.
  • For benign sublingual gland tumours, the resection of tumour and sublingual gland is the preferred treatment.
  • [MeSH-major] Carcinoma / therapy. Salivary Gland Diseases / pathology. Sublingual Gland / pathology. Sublingual Gland Neoplasms / therapy
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / therapy. Adenoma, Oxyphilic / pathology. Adenoma, Oxyphilic / therapy. Adenoma, Pleomorphic / pathology. Adenoma, Pleomorphic / therapy. Adult. Aged. Carcinoma, Adenoid Cystic / pathology. Carcinoma, Adenoid Cystic / therapy. Carcinoma, Mucoepidermoid / pathology. Carcinoma, Mucoepidermoid / therapy. Female. Humans. Male. Middle Aged. Myoepithelioma / pathology. Myoepithelioma / therapy. Reconstructive Surgical Procedures / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 International Association of Oral and Maxillofacial Surgeons. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 20605409.001).
  • [ISSN] 1399-0020
  • [Journal-full-title] International journal of oral and maxillofacial surgery
  • [ISO-abbreviation] Int J Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


23. Zhang S, Bao R, Bagby J, Abreo F: Fine needle aspiration of salivary glands: 5-year experience from a single academic center. Acta Cytol; 2009 Jul-Aug;53(4):375-82
MedlinePlus Health Information. consumer health - Salivary Gland Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine needle aspiration of salivary glands: 5-year experience from a single academic center.
  • OBJECTIVE: To investigate 5 years' experience with fine needle aspiration (FNA) of salivary glands at a single academic center.
  • STUDY DESIGN: A total of 191 salivary gland FNAs were performed at Louisiana State University Health Science Center from 2003 to 2007, and all were done on major salivary glands except for 1 case.
  • There were 5 false negatives: 2 adenoid cystic carcinomas, 1 acinic cell carcinoma, 1 polymorphous low grade adenocarcinoma and 1 metastatic basaloid squamous cell carcinoma.
  • The overall accuracy in distinguishing benign from malignant lesions was 79.1%, and the sensitivity for salivary neoplasia was 89.4%.
  • CONCLUSION: Our results are consistent with the literature that salivary gland FNA has good sensitivity, specificity and accuracy in the diagnosis of salivary neoplasms.
  • [MeSH-major] Biopsy, Fine-Needle. Salivary Gland Diseases / pathology. Salivary Gland Neoplasms / pathology. Salivary Glands / pathology

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19697720.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Chang CJ, Lin TK, Wei LC, Wen MC, Tsai HY, Wang JC, Tai MC: Carcinoma ex pleomorphic adenoma of the lacrimal gland: a case report. Ann Ophthalmol (Skokie); 2006;38(2):141-4
MedlinePlus Health Information. consumer health - Tears.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinoma ex pleomorphic adenoma of the lacrimal gland: a case report.
  • Carcinoma ex pleomorphic adenoma affects glandular structures, occurring mostly in major salivary glands and less commonly in the lacrimal gland.
  • We present a rare case in the lacrimal gland.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenoma, Pleomorphic / diagnosis. Eye Neoplasms / diagnosis. Lacrimal Apparatus Diseases / diagnosis

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17416946.001).
  • [ISSN] 1558-9951
  • [Journal-full-title] Annals of ophthalmology (Skokie, Ill.)
  • [ISO-abbreviation] Ann Ophthalmol (Skokie)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Kämmerer PW, Kreft A, Toyoshima T, Al-Nawas B, Klein MO: Misleading initial histological diagnosis of a polymorphous low-grade adenocarcinoma in situ ex pleomorphic adenoma-a case report. Oral Maxillofac Surg; 2009 Jun;13(2):99-103
Genetic Alliance. consumer health - Polymorphous low-grade adenocarcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Misleading initial histological diagnosis of a polymorphous low-grade adenocarcinoma in situ ex pleomorphic adenoma-a case report.
  • INTRODUCTION: Polymorphous low-grade adenocarcinoma (PLGA) are frequent tumours of palatinal minor salivary glands.
  • Definitive histological examination of the whole tumour revealed a small malignant fraction of the specimen besides a major part of benign tissue formations (PA).
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma, Pleomorphic / pathology. Carcinoma in Situ / pathology. Neoplasms, Multiple Primary / pathology. Palatal Neoplasms / pathology
  • [MeSH-minor] Aged. Biopsy / methods. Diagnosis, Differential. Female. Humans. Salivary Gland Neoplasms / pathology. Salivary Glands, Minor / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19189140.001).
  • [ISSN] 1865-1550
  • [Journal-full-title] Oral and maxillofacial surgery
  • [ISO-abbreviation] Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


26. Zheng J, Chen Y, Zhang J: [Basal cell adenocarcinoma of nasal septum: a case report and review of literatures]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2009 Mar;23(5):209-10
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Basal cell adenocarcinoma of nasal septum: a case report and review of literatures].
  • OBJECTIVE: To summarize clinical features, diagnosis, differential diagnosis, treatment and prognosis of basal cell adenocarcinoma.
  • METHOD: A retrospective study were subjected to one case with basal cell adenocarcinoma of the nasal septum, and the related literature were reviewed.
  • RESULT: Basal cell adenocarcinoma often occurred in the salivary glands and minor salivary glands of salivary palate and other parts.
  • Major treatment method was radical surgical resection and, if necessary, supplemented by radiotherapy.
  • CONCLUSION: Basal cell adenocarcinoma is rare seen in the salivary gland tumors.
  • [MeSH-major] Adenocarcinoma. Nasal Septum / pathology. Nose Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19522187.001).
  • [ISSN] 1001-1781
  • [Journal-full-title] Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology, head, and neck surgery
  • [ISO-abbreviation] Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] China
  •  go-up   go-down


27. Bingle L, Cross SS, High AS, Wallace WA, Rassl D, Yuan G, Hellstrom I, Campos MA, Bingle CD: WFDC2 (HE4): a potential role in the innate immunity of the oral cavity and respiratory tract and the development of adenocarcinomas of the lung. Respir Res; 2006;7:61
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We recently characterised the WFDC2 gene which encodes a two WAP domain-containing protein, initially suggested as a marker for epididymis, and showed that it is highly expressed in the lung and salivary gland.
  • Intense staining is found in major salivary glands and in minor glands of the nose, sinuses, posterior tongue and tonsil.
  • [MeSH-major] Adenocarcinoma / immunology. Epididymal Secretory Proteins / physiology. Lung Neoplasms / immunology. Mouth / immunology. Proteins / physiology. Respiratory System / immunology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gene. 1999 Oct 1;238(2):375-85 [10570965.001]
  • [Cites] Gynecol Oncol. 2005 Nov;99(2):267-77 [16061277.001]
  • [Cites] J Biol Chem. 2000 Jul 21;275(29):22136-46 [10766760.001]
  • [Cites] Biochim Biophys Acta. 2000 Oct 2;1493(3):363-7 [11018263.001]
  • [Cites] Nat Med. 2000 Oct;6(10):1147-53 [11017147.001]
  • [Cites] Cancer Res. 2000 Nov 15;60(22):6281-7 [11103784.001]
  • [Cites] Am J Respir Cell Mol Biol. 2001 Jul;25(1):84-91 [11472979.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13784-9 [11707590.001]
  • [Cites] Mol Hum Reprod. 2002 Apr;8(4):341-9 [11912282.001]
  • [Cites] Oncogene. 2002 Apr 18;21(17):2768-73 [11965550.001]
  • [Cites] Biochem Soc Trans. 2002 Apr;30(2):98-102 [12023833.001]
  • [Cites] Biochem Soc Trans. 2002 Apr;30(2):116-20 [12023837.001]
  • [Cites] Am J Respir Cell Mol Biol. 2002 Oct;27(4):436-45 [12356577.001]
  • [Cites] Biol Chem. 2002 Jul-Aug;383(7-8):1249-56 [12437112.001]
  • [Cites] Cancer Res. 2003 Jul 1;63(13):3695-700 [12839961.001]
  • [Cites] Mol Biol Cell. 2003 Nov;14(11):4376-86 [12960427.001]
  • [Cites] Am J Respir Cell Mol Biol. 2004 Feb;30(2):184-92 [12920053.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):811-9 [14990636.001]
  • [Cites] Clin Cancer Res. 2004 May 15;10(10):3291-300 [15161682.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1982 May-Jun;91(3 Pt 1):268-71 [7046595.001]
  • [Cites] Environ Health Perspect. 1990 Apr;85:71-80 [2384069.001]
  • [Cites] Biol Reprod. 1991 Aug;45(2):350-7 [1686187.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 1993 Jun;29A(6):481-92 [7687243.001]
  • [Cites] Biochem J. 1996 Jun 15;316 ( Pt 3):967-75 [8670177.001]
  • [Cites] Am J Respir Crit Care Med. 1996 Oct;154(4 Pt 1):1092-8 [8887613.001]
  • [Cites] Infect Immun. 1996 Nov;64(11):4520-4 [8890201.001]
  • [Cites] Cell. 1997 Feb 7;88(3):417-26 [9039268.001]
  • [Cites] Blood. 1997 Aug 1;90(3):1141-9 [9242546.001]
  • [Cites] Am J Respir Crit Care Med. 1997 Oct;156(4 Pt 1):1235-40 [9351627.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Dec 18;241(2):305-11 [9425267.001]
  • [Cites] Gene. 1999 Mar 18;229(1-2):101-8 [10095109.001]
  • [Cites] Biochem J. 1999 Jun 15;340 ( Pt 3):569-77 [10359639.001]
  • [Cites] FEBS Lett. 1999 Jun 11;452(3):309-13 [10386612.001]
  • [Cites] Eur Respir J. 1999 May;13(5):1029-36 [10414400.001]
  • [Cites] Infect Immun. 1999 Sep;67(9):4485-9 [10456890.001]
  • [Cites] J Pathol. 2005 Mar;205(4):491-7 [15685591.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2162-9 [15781627.001]
  • [Cites] Am J Respir Cell Mol Biol. 2005 May;32(5):443-52 [15668324.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2005 Oct;289(4):L545-53 [15937068.001]
  • [Cites] Mol Cell Proteomics. 2005 Sep;4(9):1251-64 [15951573.001]
  • [Cites] J Mol Graph Model. 1999 Apr;17(2):106-13, 134-6 [10680116.001]
  • (PMID = 16600032.001).
  • [ISSN] 1465-993X
  • [Journal-full-title] Respiratory research
  • [ISO-abbreviation] Respir. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Epididymal Secretory Proteins; 0 / Proteins; 0 / WFDC2 protein, human
  • [Other-IDs] NLM/ PMC1459147
  •  go-up   go-down






Advertisement